"Weight regain after stopping treatment may affect the long-term sustainability of the observed benefits
Instead of forcing your body to burn fat directly, they work by improving appetite control, fullness, and blood sugar response which naturally leads to eating less
HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022SEPTEMBER 2025 TABLE 644 TERNS PHARMACEUTICALS, INC.: COMPANY OVERVIEW TABLE 645 METAVIA: COMPANY OVERVIEW TABLE 646 SCOHIA PHARMA, INC.: COMPANY OVERVIEW TABLE 647 REGOR THERAPEUTICS GROUP: COMPANY OVERVIEW TABLE 648 NEURALY INC.: COMPANY OVERVIEW TABLE 649 I2O THERAPEUTICS, INC.: COMPANY OVERVIEW TABLE 650 PFIZER INC.: COMPANY OVERVIEW TABLE 651 HANMI PHARM CO., LTD.: COMPANY OVERVIEW TABLE 652 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW TABLE 653 BIOMED INDUSTRIES, INC.: COMPANY OVERVIEW FIGURE 1 GLP-1 AGONISTS MARKET SEGMENTATION & REGIONAL SCOPE FIGURE 2 GLP-1 AGONISTS MARKET: YEARS CONSIDERED FIGURE 3 GLP-1 AGONISTS MARKET: RESEARCH DESIGN FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS FIGURE 5 GLP-1 AGONISTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 FIGURE 6 GLP-1 AGONISTS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2024 FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS FIGURE 8 GLP-1 AGONISTS MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH FIGURE 9 CAGR PROJECTIONS: GLP-1 AGONISTS MARKET, 20252033 FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN GLP-1 AGONISTS MARKET FIGURE 11 GLP-1 AGONISTS MARKET: DATA TRIANGULATION METHODOLOGY FIGURE 12 GLP-1 AGONISTS MARKET, BY PRODUCT, 2025 VS
Joi + Blokes health coaches are here to: Listen to your experience you are not alone
Individual results depend on several factors, including the baseline melanin index, lifestyle factors (such as sun exposure), and consistency of treatment
After 6 months of therapy, those taking GLP1 drugs showed: Elevated risk of androgenic alopecia Elevated risk of nonscarring hair loss No significant change in telogen effluvium risk No significant change in alopecia areata risk At the 12-month mark, the pattern had shifted slightly: Continued higher risk for androgenic alopecia Continued higher risk for nonscarring hair loss A newly increased risk of telogen effluvium Still no change in risk of alopecia areata The apparent absence of a link between GLP1 medications and alopecia areata is especially notable, as isolated case reports have previously suggested an association
